Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 4/20 | 0.48 |
| ▸ | GBA2 | Q9HCG7 | 11/20 | 0.48 |
| ▸ | GBA1 | P04062 | 4/20 | 0.48 |
| ▸ | UGCG | Q16739 | 3/20 | 0.46 |
| ▸ | MGAM | O43451 | 2/20 | 0.46 |
| ▸ | SI | P14410 | 2/20 | 0.46 |
| ▸ | AGL | P35573 | 2/20 | 0.46 |
| ▸ | TBXAS1 | P24557 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Emiglitate SCHEMBL5188302 | 1.00 | KCNH2 (0.48) | KCNH2HRH3GAAGBA2GBA1 | |
| Emiglitate SCHEMBL5188305 | 1.00 | KCNH2 (0.48) | KCNH2HRH3GAAGBA2GBA1 | |
| Emiglitate SCHEMBL5616336 | 1.00 | KCNH2 (0.48) | KCNH2HRH3GAAGBA2GBA1 | |
| SCHEMBL23996617 | 0.74 | GBA2 (0.60) | GAAGBA2GBA1UGCGMGAM | |
| SCHEMBL22048754 | 0.74 | KCNH2 (0.57) | KCNH2HRH3GAATBXAS1TDP1 | |
| SCHEMBL6701399 | 0.73 | TDP1 (0.74) | KCNH2HRH3TBXAS1TDP1L3MBTL1 | |
| SCHEMBL21408538 | 0.72 | HRH3 (0.79) | KCNH2HRH3L3MBTL1MEN1LMNA | |
| SCHEMBL6867384 | 0.72 | TDP1 (0.64) | KCNH2HRH3GAATBXAS1TDP1 | |
| SCHEMBL9199244 | 0.72 | KCNH2 (0.63) | KCNH2HRH3GAATBXAS1TDP1 | |
| SCHEMBL6999600 | 0.71 | MAPK1 (0.67) | KCNH2HRH3GAATBXAS1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6500 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20250134923-A1 | SUPERABSORBENT HYDROGELS WITH LIPASE INHIBITOR | JUNION LABS PTE. LTD. (SG) | 2025-05-01 | — | — | US | claimed |
| EP-4483376-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | García Sada, Fernando (MX) | 2025-01-01 | — | — | EP | claimed |
| WO-2024255777-A1 | GRAFT-MODIFIED MESOPOROUS SILICA, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 厦门君德医药科技有限公司 | 2024-12-19 | — | — | WO | claimed |
| US-20240366579-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GPR40 AGONIST AND SGLT-2 INHIBITOR | ILDONG PHARMACEUTICAL CO., LTD. (KR) | 2024-11-07 | — | — | US | claimed |
| EP-4392044-A2 | SUPERABSORBENT HYDROGELS WITH LIPASE INHIBITOR | Junion Labs Pte. Ltd. (SG) | 2024-07-03 | — | — | EP | claimed |
| EP-4329756-A1 | PHARMACEUTICAL COMPOSITION COMPRISING GPR40 AGONIST AND SGLT-2 INHIBITOR | Ildong Pharmaceutical Co., Ltd. (KR) | 2024-03-06 | — | — | EP | claimed |
| US-20230322777-A1 | N1-Pyrazolospiroketone Acetyl-CoA Carboxylase Inhibitors | PFIZER INC. (US) | 2023-10-12 | — | — | US | claimed |
| WO-2023161832-A1 | MEASUREMENT, DIAGNOSIS, TREATMENT AND MANAGEMENT OF METABOLIC SYNDROME | GARCIA SADA FERNANDO (MX) | 2023-08-31 | — | — | WO | claimed |
| US-20230266340-A1 | Measurement, Diagnosis, Treatment and Management of Metabolic Syndrome | SILTI AG (CH) | 2023-08-24 | — | — | US | claimed |
| WO-2000028989-A1 | PHARMACEUTICAL COMPOSITION FOR MODIFIED RELEASE OF AN INSULIN SENSITISER AND ANOTHER ANTIDIABETIC AGENT | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-05-25 | — | — | WO | claimed |
| EP-1001784-A1 | TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND ALPHA GLUCOSIDASE INHIBITOR | SMITHKLINE BEECHAM PLC (GB) | 2000-05-24 | — | — | EP | claimed |
| WO-2000027434-A1 | COMBINATIONS COMPRISING A BETA-AGONIST AND A FURTHER ANTIDIABETIC AGENT | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-05-18 | — | — | WO | claimed |
| EP-0638317-B1 | Pharmaceutical composition comprising glucosidase- and/or amylaseinhibitors, and a lipase inhibiting agent | HOFFMANN LA ROCHE (CH) | 2000-03-15 | — | — | EP | claimed |
| EP-0975343-A1 | TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE AND ALPHA-GLUCOSIDASE INHIBITOR | SMITHKLINE BEECHAM PLC (GB) | 2000-02-02 | — | — | EP | claimed |
| WO-1999045973-A1 | DISPOSABLE ABSORBENT ARTICLE HAVING A SKIN CARE COMPOSITION CONTAINING AN ENZYME INHIBITOR | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-16 | — | — | WO | claimed |
| WO-1999026606-A2 | SUSTAINED RELEASE FORMULATIONS COMPRISING α-GLUCOSIDASE-INHIBITORS | BAYER AKTIENGESELLSCHAFT (DE) | 1999-06-03 | — | — | WO | claimed |
| WO-1999003478-A1 | TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE, INSULIN SECRETAGOGUE AND ALPHA GLUCOCIDASE INHIBITOR | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-01-28 | — | — | WO | claimed |
| WO-1998057635-A1 | TREATMENT OF DIABETES WITH THIAZOLIDINEDIONE AND ALPHA-GLUCOSIDASE INHIBITOR | SMITHKLINE BEECHAM PLC (GB) | 1998-12-23 | — | — | WO | claimed |
| EP-0638317-A1 | Pharmaceutical composition | F. HOFFMANN-LA ROCHE AG (CH) | 1995-02-15 | — | — | EP | claimed |